Focal Therapy Options for Localized Prostate Cancer

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci describes his approach to diagnosing patients with prostate cancer, highlighting prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) as critical to cancer detection.

A prostate cancer specialist breaks down prostate cancer staging and grading and identifies several shortcomings of established risk stratification methods for patients with clinically localized disease.

Dr Emberton provides a historical perspective of treatment options for clinically localized prostate cancer and discussed how use of these options has evolved over time.

Insights on the drawbacks of older treatment approaches for clinically localized prostate cancer and how strategically implementing focal therapies may address remaining unmet needs and clinical challenges.

An in-depth discussion of emerging focal therapy options for clinically localized prostate cancer.

Dr Mark Emberton reviews safety and efficacy data supporting the use of focal therapy in patients with prostate cancer.

An oncologic urologist from the United Kingdom (UK) discusses the diffusion of focal therapy options for clinically localized prostate cancer in the United States and UK.

A focused discussion on how the availability and use of focal therapy technology has changed treatment paradigms and affected patient outcomes.

An experienced clinician shares his personal experience with preventing and managing side effects related to focal therapy in patients with clinically localized prostate cancer.

An expert’s brief commentary on follow-up strategies in patients receiving focal therapy, including monitoring for disease relapse or recurrence.

Dr Mark Emberton shares what developments are visible on the horizon and what they represent for the future of focal therapy and treatment of clinically localized prostate cancer.